share_log

bluebird bio | 8-K: Current report

SEC announcement ·  Jan 4 00:00
Summary by Moomoo AI
bluebird bio, Inc., a biotechnology company, has announced the signing of a second outcomes-based agreement for its recently FDA-approved drug LYFGENIA. This agreement expands the coverage of LYFGENIA to approximately 200 million lives. LYFGENIA, which received FDA approval on December 8, 2023, is designed to treat sickle cell disease in patients aged 12 and older with a history of vaso-occlusive events. The company plans to provide additional updates on the commercial launch of LYFGENIA at the upcoming 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024. This information was disclosed in a Form 8-K report filed with the Securities and Exchange Commission, which is not deemed filed for purposes of Section 18 of the Exchange Act nor incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, unless specifically referenced in such filings.
bluebird bio, Inc., a biotechnology company, has announced the signing of a second outcomes-based agreement for its recently FDA-approved drug LYFGENIA. This agreement expands the coverage of LYFGENIA to approximately 200 million lives. LYFGENIA, which received FDA approval on December 8, 2023, is designed to treat sickle cell disease in patients aged 12 and older with a history of vaso-occlusive events. The company plans to provide additional updates on the commercial launch of LYFGENIA at the upcoming 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024. This information was disclosed in a Form 8-K report filed with the Securities and Exchange Commission, which is not deemed filed for purposes of Section 18 of the Exchange Act nor incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, unless specifically referenced in such filings.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more